|
布村 多佳子
Department School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine Position Associate Professor |
|
| Article types | Original article |
| Language | English |
| Peer review | Peer reviewed |
| Title | A Multicentre, Large-Scale, Observational Study of Tocilizumab in Patients with Takayasu Arteritis in Japan: The ACT-Bridge Study. |
| Journal | Formal name：Modern rheumatology Abbreviation：Mod Rheumatol ISSN code：14397609/14397595 |
| Volume, Issue, Page | pp.- |
| Author and coauthor | Harigai Masayoshi, Miyamae Takako, Hashimoto Hideyuki, Yoshida Amika, Yamashita Katsuhisa, Nakaoka Yoshikazu |
| Authorship | 2nd author |
| Publication date | 2022/09 |
| Summary | OBJECTIVES:We evaluated the real-world tolerability and effectiveness of tocilizumab in Japanese patients with Takayasu arteritis (TAK).METHODS:Patients with TAK who had not received tocilizumab in the previous 6 months were enrolled in ACT-Bridge, a phase 4, observational study, from 66 Japanese institutions (enrolment period, September 2017 to September 2020) and received weekly subcutaneous tocilizumab 162 mg (observation period, 52 weeks).RESULTS:Among 120 patients included (mean age, 38.4 years; mean disease duration, 7.7 years; treated for relapse, 50.8%; previous immunosuppressant use, 57.5%; glucocorticoid use at baseline, 97.5%), 49 (40.8%) reported adverse events (AEs). The most common AE of special interest was serious infection (7.5%). Relapse was observed in 24 (20.0%) patients (0.8%, 2.5% and 16.7% reporting ≥3, 2 and 1 relapse, respectively). The reasons for diagnosing relapse included chest and back pain (45.8%), neck pain (25.0%), fatigue (16.7%), fever and headache (12.5% each), abnormal imaging findings (50.0%) and elevated inflammatory markers (16.7%). At the last observation, 83.0% of relapse-free patients recorded a concomitant glucocorticoid dose (prednisolone equivalent) <10 mg/day.CONCLUSIONS:This study demonstrated the effectiveness of tocilizumab in patients with TAK, with no new safety concerns. Tocilizumab plus glucocorticoids may be considered a treatment option for TAK. |
| DOI | 10.1093/mr/roac099 |
| PMID | 36057089 |